- NASH Fatty Liver Disease (Inverness, FL)
- NASH Nonalcoholic Steatohepatitis (Fleming Island, FL)
Fatty Liver Disease Research
We are conducting a new research study for people with Fatty Liver Disease (NASH).
The purpose of this research study is to assess the effectiveness and safety of an investigational medication for the treatment of liver fibrosis in adults with NASH.
You may be eligible if you:
- Are 18 to 75 years old
- Have Fatty Liver Disease (NASH) and are able to undergo a liver biopsy
There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study related investigational medication (or placebo). No health insurance is required to participate.
For more information call:
Overweight, high blood pressure, or diabetes may be a sign of undiagnosed liver disease called Nonalcoholic Steatohepatitis (NASH). There are often no outward signs or symptoms associated with NASH.
The most common symptoms are:
- Pain in the upper right abdomen (usually mild)
We are conducting a research study for people who have NASH. This study will be evaluating the safety and effectiveness of an investigational oral medication (EDP-305).
You may be eligible if you:
- Are aged 18 to 75 years old
- have a Body Mass Index (BMI) between 25 and 45 (Click here for a BMI Calculator)
- have NASH based on the results of study screening procedures
There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study related investigational medication (or placebo), procedures and medical exams at no cost, as well as reimbursement for time and travel. No health insurance is required to participate.
For more information call
If you have Fatty Liver, NASH or NAFLD, you may qualify for one of our studies.
Qualified volunteers may receive at no cost:
- investigational medication
- study-related care from a local doctor
- possible compensation
Ask your doctor or contact our clinic for more information.
- What is NASH? A Silent Liver Disease…
The liver is the second largest organ in the body. Its function is to process everything we eat or drink and filter out any harmful substances from the blood. When there is too much fat in one’s liver, the filtration process is interrupted and can become a health problem.
It is estimated that 25% of the world has Non-alcoholic Fatty Liver Disease (NAFLD), a precursor to NASH or Non-Alcoholic Steatohepatitis. NASH is associated with obesity, cardiovascular disease, type 2 diabetes and metabolic syndrome. It is now the most common liver disorder in the United States and the number one reason for liver transplants.
Starting as Fatty Liver Disease and then progressing to NASH, the buildup of fat in the liver can lead to inflammation of the liver and liver cell damage. Progression of NASH leads to fibrosis or stiffening of the liver and cirrhosis or scarring of the liver. NAFLD and NASH are both silent diseases with few symptoms even if the diseases progress to cirrhosis.
Physicians can monitor liver function blood tests as well as abdominal ultrasounds and liver Fibroscans to determine if you are at risk of developing NAFLD and NASH. However, the only way to definitely determine of you have NASH is to perform a liver biopsy.
The most common treatment for fatty liver disease is weight loss to reduce the fat in the liver. It is estimated that losing up to 3 to 5% of your body weight can help reduce the fat in the liver. Losing 10% of body weight may help reduce inflammation and even fibrosis in the liver. Currently, there are no medications which have been approved to treat fatty liver disease; however, many are in late stage development with promising results.
To learn more about current clinical trial opportunities for fatty liver disease and NASH, please contact us.
Fatty Liver, NASH or NAFLD research is enrolling at:
- Fleming Island, Inverness, Jacksonville